Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer
Authors
Keywords
-
Journal
Expert Opinion on Orphan Drugs
Volume 2, Issue 12, Pages 1331-1340
Publisher
Informa Healthcare
Online
2014-09-23
DOI
10.1517/21678707.2014.962514
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
- (2017) S. I. Sherman et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
- (2014) Frédéric Illouz et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers
- (2014) Robert Shumaker et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
- (2014) Ramona Dadu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
- (2014) Ze-Feng Zhang et al. PLoS One
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Long-Term Cardiovascular Mortality in Patients With Differentiated Thyroid Carcinoma: An Observational Study
- (2013) Esther N. Klein Hesselink et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of TKI-induced diarrhea in cancer patients
- (2013) Joanne M. Bowen Current Opinion in Supportive and Palliative Care
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
- (2012) Wei-Xiang Qi et al. INTERNATIONAL JOURNAL OF CANCER
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
- (2012) Sophie Leboulleux et al. LANCET ONCOLOGY
- Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis
- (2012) Jiajie Zang et al. PLoS One
- The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid Gland
- (2012) Iain J. Nixon et al. THYROID
- E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
- (2011) Hilary Glen et al. BMC CANCER
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer
- (2011) M Schlumberger et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
- (2010) Ron J. Keizer et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry
- (2010) John D. Cramer et al. SURGERY
- Tyrosine kinase inhibitors and the thyroid
- (2009) Steven I. Sherman BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
- (2009) Hassane Izzedine et al. EUROPEAN JOURNAL OF CANCER
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- (2009) David S. Cooper et al. THYROID
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Chemotherapy with Doxorubicin in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium
- (2008) A. Matuszczyk et al. HORMONE AND METABOLIC RESEARCH
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search